Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 13/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 13/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 10/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 10/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948300 | 0.90 | CYP17A1 (0.46) | GPR65KCNQ3KCNQ2P2RX3CYP17A1 | |
| SCHEMBL1970778 | 0.90 | CYP17A1 (0.46) | GPR65KCNQ3KCNQ2P2RX3CYP17A1 | |
| SCHEMBL3344049 | 0.78 | AAK1 (0.45) | KCNQ3KCNQ2P2RX3CYP17A1AAK1 | |
| SCHEMBL1971452 | 0.77 | GPR65 (0.43) | GPR65KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL16879643 | 0.75 | ATR (0.44) | P2RX3AAK1 | |
| SCHEMBL29953353 | 0.74 | ATR (0.41) | P2RX3CYP17A1AAK1 | |
| SCHEMBL535514 | 0.74 | ATR (0.43) | P2RX3AAK1 | |
| SCHEMBL1581324 | 0.72 | ATR (0.42) | P2RX3CYP17A1AAK1 | |
| SCHEMBL12584018 | 0.72 | MAPKAPK2 (0.43) | P2RX3AAK1 | |
| SCHEMBL29364468 | 0.72 | ATR (0.42) | P2RX3CYP17A1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902195-B2 | Pyridine [3,4-b] pyrazinones | PHARMACIA & UPJOHN COMPANY LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | PFIZER INC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | CYP2B6, CYP2D6, CYP4B1 | GPR65 3113/4885KCNQ3 514/4885KCNQ2 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.